Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 6/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18857527 | 1.00 | LMNA (0.48) | LMNAGBA1PRKCAPTPN1SMN1; SMN2 | |
| SCHEMBL20832189 | 1.00 | LMNA (0.48) | LMNAGBA1PRKCAPTPN1SMN1; SMN2 | |
| SCHEMBL9838955 | 1.00 | LMNA (0.48) | LMNAGBA1PRKCAPTPN1SMN1; SMN2 | |
| SCHEMBL3394583 | 0.87 | — | — | |
| SCHEMBL22601799 | 0.87 | — | — | |
| SCHEMBL24114686 | 0.87 | — | — | |
| SCHEMBL9130905 | 0.87 | — | — | |
| SCHEMBL9131631 | 0.87 | — | — | |
| SCHEMBL4378652 | 0.87 | — | — | |
| SCHEMBL3390444 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1991002741-A1 | SUGAR ALCOHOL DERIVATIVES, A PROCESS FOR PREPARING 3-DEOXY-2-OCTULOSONIC ACID AND 3-DEOXY-2-HEPTULOSONIC ACID COMPOUNDS AND DERIVATIVES | RIJKSUNIVERSITEIT TE LEIDEN (NL) | 1991-03-07 | — | — | WO | claimed |
| US-11696891-B2 | Glucono delta-lactone for treatment of vaginal fungal infections | GEDEA BIOTECH AB (SE) | 2023-07-11 | — | — | US | disclosed |
| US-20220031640-A1 | FORMULATIONS FOR EPIDURAL REPAIR | CLARIDEI LABORATORIES, INC. | 2022-02-03 | — | — | US | disclosed |
| WO-2021226330-A1 | AGENTS TO PREVENT TISSUE DAMAGE FROM CLOSTRIDIUM DIFFICILE INFECTIONS BY INHIBITION OF THE GUT-DAMAGING BACTERIAL TOXINS TCDA AND TCDB | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2021-11-11 | — | — | WO | disclosed |
| US-11135184-B2 | Formulations for epidermal repair | CLARIDEI LABORATORIES, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210212937-A1 | GLUCONO DELTA-LACTONE FOR TREATMENT OF VAGINAL FUNGAL INFECTIONS | GEDEA BIOTECH AB (SE) | 2021-07-15 | — | — | US | disclosed |
| US-10993907-B2 | Glucono delta-lactone for treatment of vaginal fungal infections | GEDEA BIOTECH AB (SE) | 2021-05-04 | — | — | US | disclosed |
| US-10918652-B2 | Compositions for the treatment of dermatological diseases and disorders | CLARIDEI LABORATORIES, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200253925-A1 | GLUCONIC ACID DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF MICROBIAL INFECTIONS | GEDEA BIOTECH AB (SE) | 2020-08-13 | — | — | US | disclosed |
| US-20190336517-A1 | COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES AND DISORDERS | CLARIDEI LABORATORIES, INC. (US) | 2019-11-07 | — | — | US | disclosed |
| US-20190090527-A1 | EDIBLE CANNABINOID COMPOSITIONS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2019-03-28 | — | — | US | disclosed |
| WO-2017174731-A1 | GLUCONO DELTA-LACTONE FOR TREATMENT OF VAGINAL FUNGAL INFECTIONS | GEDEA BIOTECH AB (SE) | 2017-10-12 | — | — | WO | disclosed |
| US-20170173056-A1 | COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES AND DISORDERS | CLARIDEI LABORATORIES, INC. | 2017-06-22 | — | — | US | disclosed |
| WO-2008086783-A2 | PLATINUM COMPLEX | DEMEDTS ARNOUD (DE) | 2008-07-24 | — | — | WO | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| WO-1991002741-A1 | SUGAR ALCOHOL DERIVATIVES, A PROCESS FOR PREPARING 3-DEOXY-2-OCTULOSONIC ACID AND 3-DEOXY-2-HEPTULOSONIC ACID COMPOUNDS AND DERIVATIVES | RIJKSUNIVERSITEIT TE LEIDEN (NL) | 1991-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696891-B2 | Glucono delta-lactone for treatment of vaginal fungal infections | CYP51A1, HSD17B11, UGGT1 | LMNA 3583/4885GBA1 57/4885PRKCA 599/4885 |
| US-10993907-B2 | Glucono delta-lactone for treatment of vaginal fungal infections | CYP51A1, HSD17B11, UGGT1 | LMNA 3583/4885GBA1 57/4885PRKCA 599/4885 |
| US-20210212937-A1 | GLUCONO DELTA-LACTONE FOR TREATMENT OF VAGINAL FUNGAL INFECTIONS | CYP51A1, HSD17B11, UGGT1 | LMNA 3583/4885GBA1 57/4885PRKCA 599/4885 |
| US-20170173056-A1 | COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES AND DISORDERS | CUTA, TYR, DSG1 | LMNA 3610/4885GBA1 324/4885PRKCA 2171/4885 |
| US-10918652-B2 | Compositions for the treatment of dermatological diseases and disorders | CUTA, TYR, DSG1 | LMNA 3610/4885GBA1 324/4885PRKCA 2171/4885 |
| US-20220031640-A1 | FORMULATIONS FOR EPIDURAL REPAIR | CUTA, EPHB1, EPHB2 | LMNA 1173/4885GBA1 1405/4885PRKCA 4741/4885 |
| US-20200253925-A1 | GLUCONIC ACID DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF MICROBIAL INFECTIONS | FUT6, UGGT1, MGAM | LMNA 4638/4885GBA1 61/4885PRKCA 2067/4885 |
| US-20190336517-A1 | COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES AND DISORDERS | CUTA, TYR, DSG1 | LMNA 3610/4885GBA1 324/4885PRKCA 2171/4885 |
| US-11135184-B2 | Formulations for epidermal repair | KRT18, CUTA, DSG1 | LMNA 2396/4885GBA1 3094/4885PRKCA 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.